What drugs does IMMUNOMEDICS INC make?

IMMUNOMEDICS INC has 1 FDA-approved drugs including TRODELVY.

What therapeutic areas does IMMUNOMEDICS INC focus on?

IMMUNOMEDICS INC focuses primarily on Oncology.

← Back

Data updated: Jun 28, 2026

IMMUNOMEDICS INC

Biotech

Oncology

IMMUNOMEDICS INC is a biotechnology company focused on Oncology.

2020

Since

Drugs

Trials

New Drugs (2yr)

FDA Novel Drug Designations

(2020)

1 Novel 1 First-in-Class 1 Orphan 1 Breakthrough 1 Accelerated 1 Priority Review 1 Fast Track

See 1 novel approval →

2020 TRODELVY (SACITUZUMAB GOVITECAN-HZIY) First-in-Class · Orphan · Breakthrough · Priority Review · Accelerated · Fast Track

IMMUNOMEDICS INC's Key Drugs

IMMUNOMEDICS INC's core commercial portfolio centers on TRODELVY, spanning Oncology — its most strategically important drugs approved in the last 15 years.

TRODELVY

Oncology

Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC)

Trop-2 Approved 2020

IMMUNOMEDICS INC's Recent FDA Approvals

New NDA/BLA approvals for IMMUNOMEDICS INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

IMMUNOMEDICS INC's Therapeutic Areas

IMMUNOMEDICS INC's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 100%

1 drugs

IMMUNOMEDICS INC's Top Competitors

IMMUNOMEDICS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.